Microvirin-N Lectin for Specific Mycobacterium tuberculosis Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current TB diagnostic tests face challenges with low sensitivity and specificity, particularly in HIV-positive patients, due to cross-reactivity with non-tuberculous mycobacteria and variable LAM concentrations, limiting early diagnosis and treatment in resource-intensive settings.

Innovation Solution

The use of microvirin-N (MVN), a cyanobacterial lectin with sub-picomolar binding affinity to mannose-capped lipoarabinomannan (ManLAM), in conjunction with a monoclonal antibody, to selectively capture and detect ManLAM, enhancing the specificity and sensitivity of TB diagnostic assays.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional TB diagnostic tests (smear microscopy, chest radiography) are used, then resource requirements are reduced, but sensitivity and specificity deteriorate

Engineering Contradiction:

Improvediagnostic accuracyVSAvoidresource intensity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent replaces mechanical/optical detection methods (smear microscopy, chest radiography) with a biochemical detection system using microvirin-N lectin that specifically binds to ManLAM. This substitution enables high sensitivity and specificity detection of TB biomarkers in urine samples without requiring complex equipment or specialized facilities, thus improving diagnostic accuracy while reducing resource requirements.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the detection parameter from visual inspection of smears or radiographs to quantitative measurement of ManLAM concentration through lectin binding affinity. By using microvirin-N with sub-picomolar binding affinity to ManLAM, the system achieves superior sensitivity and specificity while maintaining simplicity suitable for low-resource settings.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If LAM-based rapid diagnostic tests are used, then sensitivity improves, but specificity deteriorates due to cross-reactivity with non-tuberculous mycobacteria

Engineering Contradiction:

ImprovesensitivityVSAvoidspecificity

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent applies local quality by using microvirin-N lectin that specifically recognizes and binds to the mannose-capped structure (ManLAM) of lipoarabinomannan. This localized molecular recognition at the carbohydrate cap region distinguishes M. tuberculosis ManLAM from non-tuberculous mycobacteria that lack this specific capping structure, thereby maintaining high sensitivity while improving specificity to reduce false positives.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent introduces microvirin-N lectin as an intermediary molecule that mediates specific recognition between the detection system and ManLAM. This lectin intermediary provides selective binding to the mannose caps of ManLAM, enabling differentiation from other mycobacterial LAM variants and resolving the cross-reactivity issue while preserving sensitivity.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If early diagnosis in HIV-positive patients is pursued, then mortality rate improves, but diagnostic challenge increases due to variable LAM concentrations

Engineering Contradiction:

Improvemortality reductionVSAvoiddetection challenge

Core Design Contradiction:

ReliabilityVSDifficulty of detecting and measuring

Solution Approach 1:

The patent changes the detection approach from relying on variable LAM concentrations in different patient populations to using a lectin-based system with consistent sub-picomolar binding affinity to ManLAM. The microvirin-N lectin provides uniform detection performance across HIV-positive and HIV-negative patients, overcoming the variability issue and enabling reliable early diagnosis in high-risk populations to reduce mortality.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces concentration-dependent detection methods with a affinity-based lectin binding system. The microvirin-N lectin's specific molecular recognition of ManLAM provides consistent detection sensitivity regardless of the patient's immune status or LAM production variability, thereby facilitating reliable early diagnosis in HIV-positive patients and reducing mortality.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

MVN-based assays demonstrate improved specificity and sensitivity for detecting ManLAM, reducing false positives and enabling early diagnosis of TB, especially in HIV-positive patients, with potential for point-of-care applications in low-resource settings.

Implementation Method 1

microvirin-N (MVN), a cyanobacterial lectin with sub-picomolar binding affinity to mannose-capped lipoarabinomannan (ManLAM)

Methodology Applied

Scientific EffectLectin-carbohydrate binding:

Data Source

PatentUS20240085416A1Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan

Publication Date: 2024.03.14 UNIVERSITY OF CAPE TOWN

AI summary

The present disclosure is directed to the use of microvirin-N in the detection of Mycobacterium tuberculosis infections.